Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
 |
AIDS Treat News. 1999 Jan 22;(No 311):6-8. Unique Identifier : AIDSLINE AIDS/20700017
Scondras D
Abstract: Drugs manufactured in India are 1,000 to 4,000 percent cheaper than the same product in U.S. pharmacies. Because of the possible effect on profits, drug companies are working hard to stop India and other nations that make inexpensive copies of lifesaving medicines. Most drugs are inexpensive to manufacture, but U.S. drug companies charge what the market will bear as they strive to recover research and development costs and make a profit for shareholders. It is suggested that the public good would be better served if government took a more active role in fighting HIV.
000330
A0030932
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .